GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akero Therapeutics Inc (STU:0K4) » Definitions » Short Percentage of Float

Akero Therapeutics (STU:0K4) Short Percentage of Float


View and export this data going back to 2020. Start your Free Trial

What is Akero Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Akero Therapeutics's Short Percentage of Float

For the Biotechnology subindustry, Akero Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akero Therapeutics's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akero Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Akero Therapeutics's Short Percentage of Float falls into.


;
;

Akero Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akero Therapeutics Inc (STU:0K4) » Definitions » Short Percentage of Float
Comparable Companies
CRSP SWTX SRRK CRNX ACLX MRUS RARE ZLAB XENE SLNO VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
AKRO:USA 0K4:Germany
Address
601 Gateway Boulevard, Suite 350, South San Francisco, CA, USA, 94080
Website
https://www.akerotx.com
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Akero Therapeutics Headlines

No Headlines